Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year

Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-Year

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Not Medical Advice: Read Before Proceeding This article is a market analysis for informational purposes only and does not constitute medical advice. "Best" in this context is defined by convenience, transparency, and access to services, not by clinical superiority or guaranteed health outcomes. Evaluation by a licensed clinician is required for sermorelin, and prescription approval is not guaranteed. Compounded medications are not FDA-approved; FDA does not verify their safety, effectiveness, or quality before they are marketed. Affiliate commissions may be earned, but do not impact the analysis. Always check current terms and consult a healthcare professional for medical questions.

If you're researching sublingual sermorelin tablets for 2026—particularly as consumer interest in peptide-based wellness programs rises ahead of New Year wellness season—here are the key verification points before requesting a telehealth evaluation.

According to publicly available materials from bmiMD's website, the platform offers sermorelin in mint-flavored sublingual tablet form, positioned as a needle-free alternative to injectable growth hormone-releasing peptides. Independent medical providers evaluate eligibility via telehealth intake, with prescriptions fulfilled by licensed compounding pharmacies.

This market analysis examines what distinguishes bmiMD's sermorelin offering from a service-model perspective, what compounded medications are, what the regulatory landscape involves, and who this telehealth model may or may not align with.

Verify current bmiMD program details

Important context: According to the platform's terms, sermorelin treatment is not intended to be prescribed for anti-aging, bodybuilding, or athletic performance—any use is provider-determined based on individual medical evaluation.

Quick Verification Checklist:

• Provider independence: confirm (platform ≠ prescriber)
• Compounded medication status disclosed upfront
• Pharmacy licensing: verify via state board lookup
• Refund/cancellation terms clear if prescription denied
• Pricing transparency (promotional vs. regular rates)
• Contraindications screening included in intake
• Lab/testing requirements disclosed (or "no bloodwork" confirmed)

Why "Best Sermorelin Tablet" — Evaluation Criteria Disclosed
This analysis uses "best" based on defined, verifiable service-model factors—not subjective opinions or clinical outcome claims:

Format accessibility: Sublingual tablets (needle-free) vs. injectable sermorelin, per website materials

Provider separation transparency: According to the platform's terms, bmiMD operates as a technology platform connecting users with independent medical providers—not prescribing medications itself

Compounding disclosure standards: Website materials explicitly state sermorelin is a compounded medication not FDA-approved as a finished product

Pricing transparency: According to the website, promotional pricing (from $79/month) and regular pricing ($139/month) listed in publicly available website materials

Telehealth accessibility: Entire process (intake, provider evaluation, prescription fulfillment, delivery) operates remotely according to website materials

Refund/cancellation clarity: Terms explicitly state prescription approval not guaranteed; authorization hold released if provider determines ineligibility

These factors represent program design and disclosure quality—not medical efficacy claims. Individual clinical appropriateness must be determined by a licensed provider based on personal health factors.

Verify current bmiMD program details

How bmiMD's Sermorelin Service Operates: Three-Entity Structure
According to the platform's terms of use, three separate entities are involved in bmiMD's service—a structure that separates technology platform operations from clinical decision-making and medication dispensing:

bmiMD (Medccm Inc.) functions as the technology platform providing the website, intake process, customer service, and coordination infrastructure. According to the platform's terms, bmiMD itself is not a healthcare provider and does not prescribe medications.

Independent Medical Providers are licensed healthcare professionals who review patient information submitted through the platform and determine whether prescriptions are appropriate. These providers make clinical decisions based on health information patients provide through telehealth intake questionnaires. The platform states that prescriptions are not guaranteed—the provider may determine sermorelin is not appropriate based on individual health factors.

Compounding Pharmacies (including Precision Compounding Pharmacy in Bellmore, NY, according to website materials, though bmiMD may use other state-appropriate pharmacies) fulfill prescriptions written by the medical providers. These are licensed 503A compounding pharmacies that prepare medications according to individual prescriptions.

What topics are discussed regarding sermorelin: According to bmiMD's website, the platform positions sermorelin across four wellness categories: Weight Loss, Mood + Energy, Strength + Cardio, and healthy aging support. Materials describe topics including natural growth hormone production support, muscle maintenance, fat metabolism, sleep quality, and energy levels. These represent the brand's therapeutic positioning—not verified outcomes guaranteed for all users.

Understanding Compounded Medications: What FDA Says

Before evaluating any sermorelin service, it's essential to understand what "compounded medication" means—because this is fundamentally different from FDA-approved drugs.

According to FDA guidance: "Compounded drugs are not FDA-approved. FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed." Compounding pharmacies are licensed facilities that prepare customized medications for individual patients based on prescriptions from licensed healthcare providers.

FDA notes compounded drugs are generally intended for situations where an FDA-approved option cannot meet a patient's needs—such as when a patient requires a different dosage form, strength, or formulation not commercially available, or when a commercially manufactured drug has been discontinued.

Compounding is overseen under federal law and state pharmacy laws. FDA and state regulators share responsibility for oversight, and FDA maintains enforcement authority under applicable federal requirements. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed.

What this means for sermorelin: No FDA-approved sermorelin product is currently marketed. As a result, compounded prescription preparations are one pathway clinicians may use when they determine it is appropriate for an individual patient.

According to bmiMD's terms, the platform works with licensed 503A compounding pharmacies (including Precision Compounding Pharmacy in Bellmore, NY, per website materials) that prepare sermorelin based on individual prescriptions written by independent medical providers.

The Clinical Context: How Sermorelin Works and Why It's Discussed for Wellness

Sermorelin is a growth hormone-releasing hormone (GHRH) analog—a synthetic peptide designed to mimic the natural hormone your hypothalamus produces to signal your pituitary gland to release growth hormone (GH).

The original FDA-approved indication: Sermorelin was never FDA-approved for wellness programs, muscle building, fat loss, or sleep improvement. Its original approval was specifically for diagnostic testing of growth hormone deficiency in children—used to stimulate GH release during diagnostic procedures.

Current off-label discussion: Healthcare providers may prescribe medications for uses other than their original FDA-approved indication based on clinical judgment, available research, and patient-specific factors. This is called "off-label" prescribing and is common across medicine. An estimated 20% of all prescriptions in the U.S. are written for off-label purposes.

The physiological rationale discussed in clinical literature:

Growth hormone plays multiple roles: protein synthesis and muscle maintenance, lipolysis (fat breakdown), bone density support, sleep architecture (GH is primarily released during deep sleep), and metabolic regulation. As people age, growth hormone production declines—a phenomenon sometimes called "somatopause."

Research on GHRH peptides (including sermorelin) has explored effects on body composition, sleep quality, metabolic markers, and physical function in adults with age-related GH decline. Some studies have shown improvements in lean body mass, reductions in fat mass, enhanced sleep architecture, and positive effects on metabolic health markers in specific study populations.

Critical limitation: These are ingredient-level studies, often conducted in controlled research settings with specific populations. bmiMD's sermorelin tablets as a finished compounded product have not been clinically studied for these outcomes. Individual results in real-world use vary significantly and are not guaranteed.

Sublingual Format vs. Injectable Sermorelin: What Differs

According to bmiMD's website materials, the platform offers sermorelin in mint-flavored sublingual tablet form—tablets designed to dissolve under the tongue. This format represents a key differentiator from the more common injectable sermorelin delivery method.

Injectable Sermorelin (traditional format):

• Administration via subcutaneous injection (typically abdomen or thigh)
• Requires comfort with self-injection using insulin-style needles
• Generally requires refrigeration after reconstitution
• Well-established pharmacokinetic data from decades of clinical use
• Supplies needed: needles, alcohol wipes, sharps disposal

Sublingual Tablets (bmiMD format):

• Dissolve under tongue; absorbed through oral mucosa (per website materials)
• No needles required
• Simpler for daily routine
• Less extensive published data on bioavailability compared to injectable

Bioavailability considerations: Sublingual dosing is intended to support absorption through the oral mucosa. However, published pharmacokinetic data comparing compounded sublingual sermorelin to injections is limited. Injectable sermorelin has more established research documentation.

The Telehealth Evaluation Process: "No Bloodwork Needed" Explained

According to bmiMD's website, the platform advertises "No Bloodwork Needed" for sermorelin prescriptions. Here's what this service design feature means in context:

Traditional clinical approach: Endocrinology or wellness clinics prescribing growth hormone therapy or GHRH peptides typically conduct diagnostic lab work including IGF-1 levels (a marker of GH activity), comprehensive metabolic panels, lipid panels, thyroid function tests, and sometimes GH stimulation tests. This establishes whether a patient has clinical deficiency and creates baseline data for monitoring.

bmiMD's service design: According to website materials, bmiMD's service is designed for individuals seeking wellness support. The prescribing provider evaluates health information through a telehealth intake questionnaire and determines appropriateness based on that assessment, without requiring upfront lab work as a standard protocol.

The step-by-step process described on the website:

1. Complete online intake form with health history, current medications, symptoms, wellness goals, and conditions
2. Provider review (typically within 24 hours per website materials)
3. Clinical determination—provider decides appropriateness; prescriptions not guaranteed
4. If prescription issued, sent to partner compounding pharmacy
5. Pharmacy compounds medication and ships directly

Important clarifications:

According to the terms, "no bloodwork needed" represents the service's standard protocol—not an absolute prohibition. If the provider determines lab work is necessary for an individual case based on health history, they may request it.

The provider may decline to prescribe if health history includes contraindications (active cancer, pregnancy, nursing, certain metabolic conditions), medication interactions, or if submitted information raises clinical concerns.

According to the refund policy, if you're not approved for prescription, you're not charged—the system verifies eligibility before processing payment.

Pricing Structure and Subscription Terms

According to bmiMD's website (pricing details reflect publicly available website materials at time of publication; verify current terms on bmiMD's website before purchase), the website states sermorelin sublingual tablets are offered through subscription pricing:

3-Month Subscription (marked as "Best Value" per website materials):

• First month: $79/month (promotional pricing per website)
• Subsequent months: $139/month (per website)
• Includes: 90 sublingual tablets total (30 per month) per website materials
• Expedited shipping, US-based pharmacy formulation (per website)

Monthly Subscription:

• Regular price: $139/month (per website)
• Includes: 30 sublingual tablets (per website)
• Free shipping per website materials

According to website materials, the subscription includes:

• Regular consultations with bmiMD providers
• 24/7 provider access through patient portal
• Wellness coaching included with 3-month programs

HSA/FSA Eligibility: According to a dedicated page on the website, bmiMD states prescription products including sermorelin may qualify as eligible medical expenses for Health Savings Account (HSA) and Flexible Spending Account (FSA) reimbursement. Website notes you can use HSA/FSA card at checkout or submit receipts afterward. Eligibility and coverage vary by plan provider—verify with your specific administrator.

Cancellation terms: According to website terms, subscriptions can be canceled or paused through the account portal, except if already charged for the next month. Prescriptions already processed and sent to pharmacy are non-refundable. A $50 cancellation fee applies if canceling after intake approval but before pharmacy processing.

Verify current terms: Pricing, promotions, and subscription details are subject to change. Always confirm current pricing and program terms directly on bmiMD's website before purchase.

Verify current bmiMD program details

Who This Telehealth Model May or May Not Suit

Rather than relying on individual testimonials (which represent specific experiences and may not be typical), here's a self-assessment framework to evaluate whether bmiMD's sermorelin service aligns with your situation:

This telehealth model may align well with people who:

Prefer needle-free peptide delivery: Sublingual tablets eliminate injection requirements (per website materials)—no needles, avoids injection-site reactions associated with injections. If needle aversion has been your barrier to peptide therapy, this format addresses that obstacle.

Seek telehealth convenience: The entirely remote process (intake, consultation, prescription, delivery) eliminates geographic and scheduling barriers. If you lack access to wellness clinics in your area or can't accommodate in-person appointments, this model provides accessibility.

Understand compounded medication distinctions: If you comprehend that compounded medications are not FDA-approved as finished products and are comfortable with this regulatory framework for wellness purposes under provider supervision, this service operates within that structure.

Have realistic timeline expectations: Changes discussed in clinical literature for GHRH peptides typically occur gradually over weeks to months with consistent use. If you're seeking rapid transformation or guaranteed outcomes, that expectation doesn't align with how these peptides generally function.

Value pricing transparency: According to website materials, promotional (from $79/month) and regular pricing ($139/month) are clearly disclosed during the checkout process.

Other approaches may be preferable for people who:

Prefer FDA-approved medications: If you specifically want FDA-approved therapies for wellness programs, compounded sermorelin doesn't fit that preference. Other pathways may align better with your comfort level.

Want comprehensive lab monitoring: If you prefer thorough baseline lab testing (IGF-1 levels, metabolic panels) and ongoing monitoring to objectively track therapy effects and safety, traditional wellness clinics offer that clinical rigor. bmiMD's "no bloodwork" standard protocol doesn't provide that level of laboratory assessment.

Seek in-person medical evaluation: Telehealth offers convenience but limits hands-on physical examination. If you prefer face-to-face provider interaction and in-person clinical assessment, brick-and-mortar clinics provide that experience.

Want the most established delivery method: Injectable sermorelin has decades of pharmacokinetic research and clinical use documentation. Sublingual peptide delivery has less extensive published data. If you prioritize format with the most research backing, injectable may suit you better.

Have certain health conditions: According to website materials, certain individuals may not be eligible (for example: pregnancy/nursing, under 18, active malignancy). Eligibility is determined by the prescribing clinician based on individual health factors.

Questions to consider:

• Do you understand the regulatory difference between compounded medications and FDA-approved drugs?
• Are you comfortable with off-label use for wellness rather than diagnosed deficiency treatment?
• Have you discussed peptide therapy with your primary care provider?
• Do your wellness goals align with the gradual changes discussed in clinical literature for GHRH peptides?
• Does the telehealth model (convenience) or the traditional clinic model (comprehensive assessment) better match your healthcare preferences?

Your answers help clarify whether bmiMD's specific service design matches your health philosophy and preferences.

Timeline Expectations and Individual Variability

According to bmiMD's product page, the platform states that sermorelin "may start showing effects within weeks of consistent use." This appropriately acknowledges variability—individual response to GHRH peptides varies significantly.

Based on clinical literature discussing GHRH peptides generally, people using sermorelin may notice changes along rough patterns, though individual experiences differ widely:

First few weeks: Some people in clinical contexts report improved sleep quality as an early change—deeper sleep, better rest quality, or more consistent sleep patterns. Others notice no sleep changes. Energy level stabilization may occur for some during this timeframe.

Around 4-8 weeks: If body composition changes occur, this is typically when subtle shifts may begin—clothes fitting differently, minor changes in muscle definition, gradual fat loss patterns (particularly midsection). When these changes occur, they're usually gradual rather than dramatic.

2-3 months: Continued body composition changes may become more apparent for those who respond. Some clinical literature discusses improvements in exercise recovery—reduced muscle soreness, improved endurance. Skin quality changes (thickness, elasticity, hydration) are sometimes discussed during this timeframe in clinical contexts, though effects when they occur are typically subtle.

Important caveats:

Many people don't notice dramatic changes. Growth hormone support is not like stimulant medication with immediately obvious effects. Benefits when they occur are often gradual, subtle, and may be difficult to distinguish from other lifestyle factors (diet, exercise, sleep hygiene, stress management).

Individual response varies based on: baseline starting point (age, current hormone levels, body composition), consistency of use and timing, lifestyle factors (diet quality, exercise routine, sleep habits, stress levels), genetic factors affecting hormone receptor sensitivity, other medications or supplements, and the specific compounded formulation.

Results are not guaranteed. Topics discussed on bmiMD's website represent what the platform positions sermorelin to support—not guaranteed outcomes for all users.

Safety Profile and Clinical Considerations

According to medical literature and bmiMD's website materials, sermorelin is generally well-tolerated when used as directed under medical supervision. The following points are a high-level overview, not a complete list of risks or precautions.

Common effects when they occur (based on medical literature):

For injectable forms (not applicable to sublingual tablets): injection site reactions such as redness, swelling, or pain. For sublingual administration: altered taste, flushing or warmth in face or body, mild headache (typically transient), dizziness or lightheadedness (usually temporary), nausea (generally mild when it occurs).

Most effects when they occur are mild and typically diminish as the body adjusts. If effects persist or become bothersome, contact your prescribing provider.

Contraindications according to website materials and medical literature:

People with certain conditions may not be eligible for sermorelin; the prescribing clinician determines eligibility based on individual risk factors. Conditions that may affect eligibility include active malignancy or other significant medical history, pregnancy or nursing (safety not established), age under 18 (unless specifically prescribed for diagnosed GH deficiency under endocrinology care), or hypersensitivity to sermorelin or formulation ingredients.

Use with caution if you have: diabetes or impaired glucose tolerance (growth hormone affects insulin sensitivity and glucose metabolism; monitor blood sugar closely), thyroid disorders (GH therapy can affect thyroid function; may require thyroid medication adjustment), pituitary disorders or history of brain tumors, cardiovascular disease (growth hormone affects cardiac function and fluid balance).

Drug interactions: Growth hormone-releasing peptides may interact with insulin and diabetes medications (GH can affect insulin sensitivity), thyroid medications (GH may alter thyroid hormone levels), and corticosteroids (may blunt GH response to sermorelin).

Always inform your prescribing provider about all medications, supplements, and health conditions during your intake consultation.

This safety overview is not exhaustive and does not replace Patient Drug Education or official prescribing information. Always review full safety information that comes with your prescription and consult your prescriber or pharmacist with questions.

This is not a replacement for prescribed medical treatment for any health condition. Always consult your physician if you have health concerns, take other medications, or have questions before starting sermorelin or any prescription treatment.

Contact Information

For questions before or during use of bmiMD's service, according to the company's website, customer support is available at:

• Email: orders@bmimd.com
• Address: 420 Lexington Ave, Suite 1402, New York, NY 10170

Market Analysis Summary: Balancing Convenience Against Clinical Rigor
After reviewing bmiMD's sermorelin tablet service structure, here's the balanced assessment based on disclosed program factors:
Service Design Strengths:

Format addresses real adoption barriers: Sublingual tablet format eliminates needle requirements—a genuine obstacle for many people interested in peptide therapy. If injection aversion has prevented you from exploring GHRH peptides, this delivery method removes that barrier.

Pricing positioned below traditional clinic models: At $139/month regular pricing (or from $79/month promotional per website materials), bmiMD positions below typical wellness clinic ranges of $200-$600/month, particularly when factoring in eliminated lab costs and clinic visit fees.

Transparency about regulatory framework: The website explicitly discloses that sermorelin is a compounded medication not FDA-approved as a finished product, and that bmiMD operates as a platform connecting users with independent providers rather than prescribing medications itself. This disclosure standard exceeds some peptide vendors operating in less transparent regulatory zones.

Telehealth accessibility: The entirely remote model (intake, consultation, prescription, delivery) eliminates geographic barriers for people in areas without access to specialized wellness clinics.

Considerations to Weigh:

Compounded medication framework: You're receiving a product that FDA has not evaluated for safety, effectiveness, or quality as a finished medication. This is legal under compounding regulations, but represents a different regulatory standard than FDA-approved drugs.

"No bloodwork" model reduces clinical data: While convenient, the standard protocol of skipping baseline lab work means you lack objective markers (IGF-1 levels, metabolic panels) to monitor therapy effectiveness or safety over time. You're relying on subjective assessment rather than laboratory data.

Off-label use for purposes beyond original indication: Sermorelin was never FDA-approved for wellness programs, muscle building, or fat loss applications. You're using it for purposes beyond its original approved diagnostic indication, based on ingredient-level research and off-label prescribing patterns—not FDA-reviewed efficacy data for these specific uses. According to the platform's terms, treatment is not intended to be prescribed for anti-aging, bodybuilding, or athletic performance—any use is provider-determined based on individual medical evaluation.

Sublingual bioavailability less documented: Injectable sermorelin has decades of pharmacokinetic research. Sublingual peptide delivery has limited published bioavailability data. You're prioritizing convenience over established absorption profiles.

Realistic expectations essential: If you expect rapid, dramatic transformation, disconnect exists between those expectations and how GHRH peptides typically function. Changes when they occur are gradual, subtle, and highly variable—and don't occur for everyone despite consistent use.

Important Note: Growth hormone peptides have been under increased regulatory scrutiny in recent years, particularly when marketed for wellness programs or performance enhancement. Individuals should review current information about any compounded prescription service's compliance and regulatory standing before proceeding.

The Bottom Line:

bmiMD's sermorelin tablets represent a lower-barrier entry point into GHRH peptide therapy for people who understand they're using a compounded medication for provider-determined wellness purposes, prefer convenience and needle-free format over comprehensive clinical assessment, have realistic expectations about gradual subtle changes rather than dramatic transformation, and are comfortable with the regulatory distinctions between compounded and FDA-approved medications.

This is not a rapid transformation solution. It's a tool that may support wellness goals when used consistently under medical supervision, with full understanding of the regulatory framework and realistic expectations about individual variability in response.

Verify current bmiMD program details

Disclaimers

Content and Medical Disclaimer: This article is for informational and market analysis purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Topics discussed regarding potential applications are based on publicly available materials and general medical literature—not guarantees of individual outcomes. Sermorelin is a compounded prescription medication that requires evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Sermorelin is not a substitute for prescribed medical treatment. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting sermorelin or any new prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.

Compounded Medication Notice: Sermorelin tablets discussed in this analysis are compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. According to FDA guidance: "Compounded drugs are not FDA-approved. FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed." They are prepared by licensed pharmacies based on an individual prescription and dispensed under applicable federal and state pharmacy oversight.

Platform and Provider Separation: bmiMD (Medccm Inc.) is a technology platform and is not itself a healthcare provider. Independent medical providers review patient information and determine whether prescriptions are appropriate. Prescriptions are fulfilled by licensed compounding pharmacies. bmiMD does not control or influence the practice of medicine by the medical providers, each of whom is solely responsible for the medical care and treatment provided.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, genetic factors, consistency of use, lifestyle factors, current medications, and other individual variables. Topics discussed regarding potential applications are based on general medical literature and ingredient-level research—not clinical trials of the specific compounded product. Results are not guaranteed.

Off-Label Use: Sermorelin was originally FDA-approved for a limited pediatric diagnostic indication and is no longer marketed as an FDA-approved finished drug product. Discussion of wellness-related use reflects clinician-directed, case-by-case prescribing judgment (off-label), not FDA-approved indications. According to the platform's terms, treatment is not intended to be prescribed for anti-aging, bodybuilding, or athletic performance.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All analysis is based on publicly available information.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were based on publicly available website information at the time of publication and are subject to change without notice. Always verify current pricing and terms on the official bmiMD website before making purchase decisions.

Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with bmiMD and their healthcare provider before making decisions.

HSA/FSA Note: According to bmiMD's website, prescription products may be eligible for HSA/FSA reimbursement, but coverage policies vary by plan. Always confirm benefits directly with your HSA/FSA plan administrator before purchase.

Regulatory Scrutiny Notice: Growth hormone peptides have been subject to increased regulatory attention from FDA and FTC in recent years. Users should stay informed about current regulatory developments affecting compounded peptide therapies and verify provider and pharmacy licensing in their state.

Email: orders@bmimd.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.